SCHEMBL23536119

SCHEMBL23536119

Nc1ccccc1N1CCC(C2COCCO2)CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.51
MEN1 O00255 1/20 0.51
USP2 O75604 1/20 0.51
KMT2A Q03164 1/20 0.51
KEAP1 Q14145 1/20 0.45
ADRA2C P18825 1/20 0.43
LGMN Q99538 3/20 0.34
NPC1 O15118 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
DHFR P00374 1/20 0.32
KDM4E B2RXH2 3/20 0.31
LMNA P02545 2/20 0.31
ALDH1A1 P00352 1/20 0.31
DDB1 Q16531 1/20 0.30
CRBN Q96SW2 1/20 0.30
MKNK1 Q9BUB5 2/20 0.30
MKNK2 Q9HBH9 2/20 0.30
NCF1 P14598 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23536201 0.79 HTT (0.49) GAAMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL29932080 0.79 HTT (0.49) GAAMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL23379453 0.75 GAA (0.72) GAAMEN1USP2KMT2AKEAP1
SCHEMBL30108629 0.75 GAA (0.72) GAAMEN1USP2KMT2AKEAP1
SCHEMBL29947224 0.73 KEAP1 (0.46) GAAMEN1USP2KMT2AKEAP1
SCHEMBL29931854 0.71 MAPT (0.35) GAANPC1SMN1; SMN2LMNAALDH1A1
SCHEMBL11506767 0.71 GAA (0.72) GAAMEN1USP2KMT2AKEAP1
SCHEMBL127620 0.71 KEAP1 (0.64) GAAMEN1USP2KMT2AKEAP1
SCHEMBL30443433 0.71 KEAP1 (0.64) GAAMEN1USP2KMT2AKEAP1
SCHEMBL3435080 0.71 MEN1 (0.57) GAAMEN1USP2KMT2AKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 US disclosed
EP-4076423-A1 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2022-10-26 EP disclosed
CN-115087440-A TRPML modulators 卡斯玛治疗公司 2022-09-20 CN disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 GAA 2832/4885MEN1 782/4885USP2 4313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.